Levels of Neurospecific Peptides, Neurotransmitters and Neuroreceptor Markers in the Serum of Children with Various Sensory Disorders, Mild Cognitive Impairments and Other Neuropathology

Background. The role of recently discovered neurospecific peptides in the pathogenesis of acute and progressive neurologic disorders, their neuroprotective features, and possibilities to use them as markers for the course and prognosis of certain diseases have been actively studied in recent decades. However, neurospecific peptides are almost not studied in chronic residual diseases. In our study we measured the levels of neurospecific peptides and some other markers to achieve understanding of general neurophysiological trends in congenital and acquired chronic non-progressive brain pathology with reference to the selection of relevant groups — study objects. Objective. The aim of the study is to study patterns of neurospecific peptides, neurotransmitters and neuroreceptor markers distribution in the serum of children with various pathogenetic variants of chronic neuropathology. Methods. The study included children from 3 to 16 years old with different pathologies. The sample was divided into groups by pathology type: no sensory and neurological disorders, congenital sensory deficit due to mutation of genes expressed and not expressed in the brain, early acquired sensory deficit of multifactorial nature, congenital mild and severe organic disorders of central nervous system (CNS) in residual stage without baseline sensory deficit, acquired functional CNS disorders without baseline organic defect and sensory deficit. The following laboratory data (neurophysiological components) was studied: nerve growth factor, brain-derived neurotropic factor, neurotrophin-3, neurotrophin-4, neuregulin-1-beta-1, beta-secretase, sirtuin-1, synaptophysin, neuronal nitric oxide synthase, and anti-NR2 glutamate receptor antibodies. The parameters of cognitive activity, sense of vision, sense of smell, and acoustic sense were also evaluated. Results. The study included 274 participants. Neuropeptides and markers have shown a variable degree and range in the group spectrum of differences from normal levels. The most variable in the examined sample was NO-synthase, as well as levels of both neurotrophins, beta-secretase, and glutamate receptor marker. All visual deficits were associated with increased NO-synthase levels (p < 0.001). Neuroplasticity peptides (beta-secretase, neurotrophin-3 and 4) have been activated in all pathological conditions. Nerve growth factor and brain-derived neurotropic factor were specifically activated in mild organic CNS lesions (mild cognitive impairments), while neuregulin — in congenital genetically determined visual deficits. There was no specific activation of neuropeptides and NO-synthase level tended to decrease in cases of severe CNS lesions. Conclusion. The study results suggest that all types of early visual impairment are associated with increased physiological neuronal activity, and non-organic neurological functional disorders — mainly with increased physiological synaptic activity. General neuroplasticity processes were activated in all cases of visual deficits but more specific. However, more specific and well-studied processes were activated in mild organic CNS lesions, and neuroplasticity processes did not activate adequately in severe organic CNS lesions probably due to the limited neuronal and synaptic resources.

1. Krägeloh-Mann I. Imaging of early brain injury and cortical plasticity. Exp Neurol. 2004;190 Suppl 1:S84–S90. https://doi.org/10.1016/j.expneurol.2004.05.037

2. Karkashadze GA, Maslova OI, NamazovaBaranova LS. Current Problems of Diagnosis and Treatment of Mild Cognitive Impairments in Children. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2011;8(5):37–41. (In Russ).

3. McDouall A, Wassink G, Bennet L, et al. Challenges in developing therapeutic strategies for mild neonatal encephalopathy. Neural Regen Res. 2022;17(2):277–282. https://doi.org/10.4103/1673-5374.317963

4. Khot S, Tirschwell DL. Long-term neurological complications after hypoxic-ischemic encephalopathy. Semin Neurol. 2006;26(4):422–431. https://doi.org/10.1055/s-2006-948323

5. Dronkers NF, Ivanova MV, Baldo JV. What Do Language Disorders Reveal about Brain-Language Relationships? From Classic Models to Network Approaches. J Int Neuropsychol Soc. 2017;23(9-10):741–754. https://doi.org/10.1017/S1355617717001126

6. Hoogman M, Muetzel R, Guimaraes JP, et al. Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples. Am J Psychiatry. 2019;176(7):531–542. https://doi.org/10.1176/appi.ajp.2019.18091033

7. Anderson CA, Arciniegas DB. Cognitive sequelae of hypoxic-ischemic brain injury: a review. NeuroRehabilitation. 2010;26(1):47–63. https://doi.org/10.3233/NRE-2010-0535

8. Lu-Emerson C, Khot S. Neurological sequelae of hypoxic-ischemic brain injury. NeuroRehabilitation. 2010;26(1):35–45. https://doi.org/10.3233/NRE-2010-0534

9. Blanco-Kelly F, Tarilonte M, Villamar M, et al. Genetics and epidemiology of aniridia: Updated guidelines for genetic study. Arch Soc Esp Oftalmol (Engl Ed). 2021;96(Suppl 1):4–14. https://doi.org/10.1016/j.oftal.2021.02.002

10. Daruich A, Duncan M, Robert MP, et al. Congenital aniridia beyond black eyes: From phenotype and novel genetic mechanisms to innovative therapeutic approaches. Prog Retin Eye Res. 2022;101133. https://doi.org/10.1016/j.preteyeres.2022.101133

11. Dansault A, David G, Schwartz C, et al. Three new PAX6 mutations including one causing an unusual ophthalmic phenotype associated with neurodevelopmental abnormalities. Mol Vis. 2007;13:511–523.

12. Han CJ, Thurm A, Golden Williams C, et al. Association of brain-derived neurotrophic factor (BDNF) haploinsufficiency with lower adaptive behaviour and reduced cognitive functioning in WAGR/11p13 deletion syndrome. Cortex. 2013;49(10):2700–2710. https://doi.org/10.1016/j.cortex.2013.02.009

13. Xu S, Han JC, Morales A, et al. Characterization of 11p14-p12 deletion in WAGR syndrome by array CGH for identifying genes contributing to mental retardation and autism. Cytogenet Genome Res. 2008;122(2):181–187. https://doi.org/10.1159/000172086

14. Bakker R, Wagstaff PE, Kruijt CC, et al. The retinal pigmentation pathway in human albinism: Not so black and white. Prog Retin Eye Res. 2022;91:101091. https://doi.org/10.1016/j.pretey-eres.2022.101091

15. Neveu MM, Padhy SK, Ramamurthy S, et al. Ophthalmological Manifestations of Oculocutaneous and Ocular Albinism: Current Perspectives. Clin Ophthalmol. 2022;16:1569–1587. https://doi.org/10.2147/OPTH.S329282

16. Wang YM, Lu SY, Zhang XJ, et al. Myopia Genetics and Heredity. Children (Basel). 2022;9(3):382. https://doi.org/10.3390/children9030382

17. Ivanov AD. The Role of NGF and BDNF in Mature Brain Activity Regulation. I.P. Pavlov Journal of Higher Nervous Activity. 2014;64(2):137–146. (In Russ). https://doi.org/10.7868/S0044467714020099

18. Fahnestock M. Structure and biosynthesis of nerve growth factor. Curr Top Microbiol Immunol. 1991;165:1-26. https://doi.org/10.1007/978-3-642-75747-1_1

19. Chen WH, Mao CQ, Zhuo LL, Ong JL. Beta-nerve growth factor promotes neurogenesis and angiogenesis during the repair of bone defects. Neural Regen Res. 2015;10(7):1159–1165. https://doi.org/10.4103/1673-5374.160114

20. Furukawa S. Neurotrophins as a therapeutic tool for degenerative neuronal disorders. Rinsho Shinkeigaku. 1993;33(12):1265–1269.

21. Bothwell M. NGF, BDNF, NT3, and NT4. Handb Exp Pharmacol. 2014;220:3–15. https://doi.org/10.1007/978-3-642-45106-5_1

22. Leal G, Comprido D, Duarte CB. BDNF-induced local protein synthesis and synaptic plasticity. Neuropharmacology. 2014;76 Pt C:639–656. https://doi.org/10.1016/j.neuropharm.2013.04.005

23. Bernd P. The role of neurotrophins during early development. Gene Expr. 2008;14(4):241–250. https://doi.org/10.3727/105221608786883799

24. Zhu G, Sun C, Liu W. Effects of neurotrophin-3 on the differentiation of neural stem cells into neurons and oligodendrocytes. Neural Regen Res. 2012;7(19):1483–1487. https://doi.org/10.3969/j.issn.1673-5374.2012.19.006

25. Omar NA, Kumar J, Teoh SL. Neurotrophin-3 and neurotrophin-4: The unsung heroes that lies behind the meninges. Neuropeptides. 2022;92:102226. https://doi.org/10.1016/j.npep.2022.102226

26. Wu L, Walas SJ, Leung W, et al. Neuregulin-1 and Neurovascular Protection. In: Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Kobeissy FH, ed. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Ch. 39.

27. Talmage DA. Mechanisms of neuregulin action. Novartis Found Symp. 2008;289:74–84; discussion 84–93. https://doi.org/10.1002/9780470751251.ch6

28. Newbern J, Birchmeier C. Nrg1/ErbB signaling networks in Schwann cell development and myelination. Semin Cell Dev Biol. 2010;21(9):922–928. https://doi.org/10.1016/j.semcdb.2010.08.008

29. Kataria H, Alizadeh A, Karimi-Abdolrezaee S. Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair. Prog Neurobiol. 2019;180:101643. https://doi.org/10.1016/j.pneurobio.2019

30. Fleck D, Garratt AN, Haass C, Willem M. BACE1 dependent neuregulin processing: review. Curr Alzheimer Res. 2012;9(2):178–183. https://doi.org/10.2174/156720512799361637

31. Willem M, Lammich S, Haass C. Function, regulation and therapeutic properties of beta-secretase (BACE1). Semin Cell Dev Biol. 2009;20(2):175–182. https://doi.org/10.1016/j.semcdb.2009.01.003

32. Hampel H, Vassar R, De Strooper B, et al. The β-Secretase BACE1 in Alzheimer’s Disease. Biol Psychiatry. 2021;89(8):745–756. https://doi.org/10.1016/j.biopsych.2020.02.001

33. McDade E, Voytyuk I, Aisen P, et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol. 2021;17(11):703–714. https://doi.org/10.1038/s41582-021-00545-1

34. Kwon SE, Chapman ER. Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons. Neuron. 2011;70(5):847–854. https://doi.org/10.1016/j.neuron.2011.04.001

35. Cousin MA. Synaptophysin-dependent synaptobrevin-2 trafficking at the presynapse-Mechanism and function. J Neurochem. 2021;159(1):78–89. https://doi.org/10.1111/jnc.15499

36. Qi C, Luo LD, Feng I, Ma S. Molecular mechanisms of synaptogenesis. Front Synaptic Neurosci. 2022;14:939793. https://doi.org/10.3389/fnsyn.2022.939793

37. Nogueiras R, Habegger KM, Chaudhary N, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012;92(3):1479–1514. https://doi.org/10.1152/phys-rev.00022.2011

38. Packer M. Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors. Circ Heart Fail. 2020;13(9):e007197. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007197

39. Lu CL, Liao MT, Hou YC, et al. Sirtuin-1 and Its Relevance in Vascular Calcification. Int J Mol Sci. 2020;21(5):1593. https://doi.org/10.3390/ijms21051593

40. Wang W, Sun W, Cheng Y, et al. Role of sirtuin-1 in diabetic nephropathy. J Mol Med (Berl). 2019;97(3):291–309. https://doi.org/10.1007/s00109-019-01743-7

41. Freudenberg F, Alttoa A, Reif A. Neuronal nitric oxide synthase (NOS1) and its adaptor, NOS1AP, as a genetic risk factors for psychiatric disorders. Genes Brain Behav. 2015;14(1):46–63. https://doi.org/10.1111/gbb.12193

42. Hardingham N, Dachtler J, Fox K. The role of nitric oxide in pre-synaptic plasticity and homeostasis. Front Cell Neurosci. 2013;7:190. https://doi.org/10.3389/fncel.2013.00190

43. Nasyrova RF, Moskaleva PV, Vaiman EE, et al. Genetic Factors of Nitric Oxide’s System in Psychoneurologic Disorders. Int J Mol Sci. 2020;21(5):1604. https://doi.org/10.3390/ijms21051604

44. Ahmed SSSJ, Akram Husain RS, Suresh Kumar, Ramakrishnan V. Association Between NOS1 Gene Polymorphisms and Schizophrenia in Asian and Caucasian Populations: A Meta-Analysis. Neuromolecular Med. 2017;19(2-3):452–461. https://doi.org/10.1007/s12017-017-8460-z

45. Gao SF, Qi XR, Zhao J, et al. Decreased NOS1 expression in the anterior cingulate cortex in depression. Cereb Cortex. 2013;23(12):2956–2964. https://doi.org/10.1093/cercor/bhs285

46. Bruenig D, Morris CP, Mehta D, et al. Nitric oxide pathway genes (NOS1AP and NOS1) are involved in PTSD severity, depression, anxiety, stress and resilience. Gene. 2017;625:42–48. https://doi.org/10.1016/j.gene.2017.04.048

47. Bonvicini C, Faraone SV, Scassellati C. Common and specific genes and peripheral biomarkers in children and adults with attentiondeficit/hyperactivity disorder. World J Biol Psychiatry. 2018;19(2):80–100. https://doi.org/10.1080/15622975.2017.1282175

48. Wang J, Jin L, Zhu Y, et al. Research progress in NOS1AP in neurological and psychiatric diseases. Brain Res Bull. 2016;125:99–105. https://doi.org/10.1016/j.brainresbull.2016.05.014

49. Hawi Z, Cummins TD, Tong J, et al. The molecular genetic architecture of attention deficit hyperactivity disorder. Mol Psychiatry. 2015;20(3):289–297. https://doi.org/10.1038/mp.2014.183

50. Dobrynina LA, Krotenkova MV, Kalashnikova LA, et al NR2 glutamate receptor antibodies as a marker of ischemic lesion in cerebral microangiopathy (small vessel disease). S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(5-2):396–397. (In Russ).

51. Savchenko OA, Pavlinova EB. Long-term neurological outcomes in premature children with excitotoxic brain damage. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(9-2):37–41. (In Russ). https://doi.org/10.17116/jnevro202212209237

52. Pravdukhina GP, Skoromets AP. Dinamika psikhomotornogo razvitiya i urovnya autoantitel k retseptoram glutamata u detei s perinatal’nym gipoksicheski-ishemicheskim porazheniem TsNS. Neirokhirurgiya i nevrologiya detskogo vozrasta. 2013;(1):35–39. (In Russ).

53. Sorokina EG, Semenova ZhB, Mamontova NA, et al Autoantibodies to glutamate receptors and metabolic products of nitric oxide in blood serum of children in the acute period of brain trauma. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(3):67–72. (In Russ).

54. Dalmau J. Gleichman AJ. Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–1098. https://doi.org/10.1016/S1474-4422(08)70224-2

55. Govorin NV, Vasilyeva AI. To the assessment objectification of therapy efficiency of the patients in the first psychotic episode clinic. Siberian Herald of Psychiatry and Addiction Psychiatry. 2011;(2): 82–85. (In Russ).

56. Levite M, Ganor Y. Autoantibodies to glutamate receptors can damage the brain in epilepsy, systemic lupus erythematosus and encephalitis. Expert Rev Neurother. 2008;8(7):1141–1160. https://doi.org/10.1586/14737175.8.7.1141

57. Seredenin SB, Povarnina PYu, Gudasheva TA. An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2 S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(7):49–53. (In Russ). https://doi.org/10.17116/jnevro20181187149

58. Patent № 2126265 Russian Federation, IPC A61K 9/08, A61K 9/00, A61K 9/14, A61K 9/19, A61K 38/18, A61K 38/22, A61K 47/00, A61K 47/02, A61K 47/12, A61K 47/26, A61K 47/42, A61P 25/28. Pharmaceutical compositions with nerve growth factors: № 96105951/14: declare 16.08.1994: publ. 20.02.1999. Knepp VM, Lidgejt DM, Maskivich R, Gu L. 17 p. (In Russ).

59. Kurakhmaeva KB. Eksperimental’noe izuchenie protivoparkinsonicheskogo deistviya faktora rosta nervov, sorbirovannogo na poli(butil)tsianoakrilatnykh nanochastitsakh. [abstract of dissertation]. Moscow; 2009. (In Russ).

60. Bakaeva LM. Vliyanie neirotroficheskogo faktora golovnogo mozga (BDNF) na sostoyanie setchatki v eksperimente. [abstract of dissertation]. Moscow; 2010. (In Russ).

61. Cervellati C, Valacchi G, Zuliani G. BACE1: from biomarker to Alzheimer’s disease therapeutical target. Aging (Albany NY). 2021; 13(9):12299–12300. https://doi.org/10.18632/aging.203064

62. Hallak JEC, Maia-de-Oliveira JP, Abrao J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside. JAMA Psychiatry. 2013;70(7):668–676. https://doi.org/10.1001/jamapsychiatry.2013.1292

63. Wass C, Klamer D, Katsarogiannis E, et al. L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study. BMC Med. 2011;9:40. https://doi.org/10.1186/1741-7015-9-40

64. Filimonenko YuV, Timofeev VI. Test Vekslera, diagnostika struktury intellekta (detskii variant): Methodological guide. St. Petersburg: Imaton; 2012. 106 p. (In Russ).

65. Pashkov AV, Naumova IV, Zelenkova IV. Metody issledovaniya slukha u detei. Moscow: Pediatr; 2020. 40 p. (In Russ).

66. Patent № 2770290 Russian Federation, IPC A01B 5/08, G01N 33/497, A61J 1/06. Method for assessing the threshold of olfaction in children: № 2021118701: declare 28.06.2021: publ. 15.04.2022. Karkashadze GA, Namazova-Baranova LS, Vishneva EA, et al. 19 p. (In Russ).

67. Namazova-Baranova L, Karkashadze G, Zelenkova IV, et al. A non-randomized comparative study of olfactory and gustatory functions in children who recovered from COVID-19 (1-year follow-up). Front Pediatr. 2022;10:919061. https://doi.org/10.3389/fped.2022.919061

68. Boldyrev AA, Bryushkova EA, Vladychenskaya EA. NMDA receptors in the immune system cells. Biochemistry (Moscow). 2012;77(2):160–168. (In Russ).

69. Taylor HA, Przemylska L, Clavane EM, Meakin PJ. BACE1: More than just a β-secretase. Obes Rev. 2022l;23(7):e13430. https://doi.org/10.1111/obr.13430

70. Bazarnyi VV, Volkhina SA, Akhmanaeva EYu, Kovtun OP. The serum biomarkers in diagnostic of hypoxic ischemic affection of central nervous system in children. Klinicheskaya Laboratornaya Diagnostika = Russian Clinical Laboratory Diagnostics. 2016;61(5):283–285. (In Russ). https://doi.org/10.18821/0869-2084-2016-61-5-283-285

71. Panova MS, Panchenko AS, Ziganshin AM, Mudrov VA. Laboratory diagnosis of children’s neurodamage. Disease Treatment and Prevention. 2022;12(1):13–20. (In Russ).

72. Mikhalenko IV, Mikhalev EV. The Evaluation Neuropsychological Development in Preterm Infants with Hypoxic Brain Injury. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk — Annals of the Russian Academy of Medical Sciences. 2013;68(11):49–53. (In Russ).

73. Krasnorutskaia ON, Bugrimov DYu, Zuikova AA, et al. Nerve growth factor – a diagnostic marker of the degree of neurological deficiency in children. Sovremennye problemy nauki i obrazovaniya. 2016;(5):57. (In Russ).

74. Krasnolobova SA. Autoantitela k faktoru rosta nervov pri narusheniyakh razvitiya nervnoi sistemy (v eksperimente i klinike). [abstract of dissertation]. Moscow; 2005. (In Russ).

75. Sokolova MG. Neurotrophinsmarkers reparative-destructive processes in children with cerebral palsy. Herald of the Northwestern State Medical University named after I.I. Mechnikov. 2015;7(1):93–96. (In Russ).